Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe

1998 ◽  
Vol 34 (14) ◽  
pp. 2184-2190 ◽  
Author(s):  
J Faivre ◽  
D Forman ◽  
J Estève ◽  
M Obradovic ◽  
M Sant
Keyword(s):  
Pancreatic Cancer ◽  
Liver Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Primary Liver Cancer ◽  
Tract Cancer

scholarly journals Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 252
Author(s):  
Shunsuke Kato
Keyword(s):  
Pancreatic Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Cancer Genome ◽  
Current Status ◽  
Driver Mutations ◽  
Hereditary Cancer Syndrome ◽  
Routine Practice ◽  
Tract Cancer ◽  
Basket Trials

The prognosis of patients with solid tumours has remarkably improved with the development of molecular-targeted drugs and immune checkpoint inhibitors. However, the improvements in the prognosis of pancreatic cancer and biliary tract cancer is delayed compared to other carcinomas, and the 5-year survival rates of distal-stage disease are approximately 10 and 20%, respectively. However, a comprehensive analysis of tumour cells using The Cancer Genome Atlas (TCGA) project has led to the identification of various driver mutations. Evidently, few mutations exist across organs, and basket trials targeting driver mutations regardless of the primary organ are being actively conducted. Such basket trials not only focus on the gate keeper-type oncogene mutations, such as HER2 and BRAF, but also focus on the caretaker-type tumour suppressor genes, such as BRCA1/2, mismatch repair-related genes, which cause hereditary cancer syndrome. As oncogene panel testing is a vital approach in routine practice, clinicians should devise a strategy for improved understanding of the cancer genome. Here, the gene mutation profiles of pancreatic cancer and biliary tract cancer have been outlined and the current status of tumour-agnostic therapy in these cancers has been reported.

Dose-finding study using oxaliplatin (Ox) in combination with fixed dose gemcitabine (Gem) and radiotherapy (RT) in patients with locally advanced pancreatic or biliary tract cancer (PBCa)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14028-14028
Author(s):  
M. Peeters ◽  
T. Boterberg ◽  
E. Monsaert ◽  
I. Borbath ◽  
A. Demols ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Locally Advanced ◽  
Dose Finding ◽  
Fixed Dose ◽  
Karnofsky Performance Score ◽  
Weekly Dose ◽  
Tract Cancer ◽  
Grade 3

14028 Background: Prognosis of inoperable PBCa is poor. Large randomized studies in pancreatic cancer showed a better survival in patients (pts) with locally advanced (LA) in comparison with metastatic disease. Data on radiochemotherapy are scarce in pts with LA disease. Therefore, we performed this multicenter, phase I study on the combination of radiotherapy and Gem/Ox. This regimen showed superior activity to Gem alone in pancreatic cancer (Louvet C et al. JCO 2005;23:3509–16.) Methods: After signed informed consent, pts with LA pancreatic cancer (n = 14) or biliary tract cancer (n=1) were included. They received two cycles of Gem/Ox1 followed by 5 weeks of RT (25 fractions of 1.8 Gy up to a total dose of 45 Gy) in combination with a weekly fixed dose of Gem (300 mg/m2 in 30’) and an escalating weekly dose of Ox (levels: 40/50/60 mg/m2). NCI-CTC 2.0 was used weekly to score treatment-related toxicity in all pts. Results: Today, 15 pts. with a median age of 61 y (range: 44–74), median Karnofsky performance score 90 (range: 70–100) and M/F = 8/7 were included. Upto 60 mg/m2 Ox, no disease limiting toxicity (DLT) occured. Grade 3 toxicity included nausea (n = 1), neutropenia (n = 3) and thrombocytopenia (n = 1). This latter patient was treated with 40 mg/m2 Ox and subsequently also experienced a grade 4. One patient receiving 50 mg/m2 Ox developed a grade 4 thrombocytopenia. Most frequent grade 1/2 toxicity was nausea (n = 8, 53%), thrombocytopenia (n = 5, 33%) and diarrhea (n = 5, 30%). Fourteen out of 15 received the full course of radiotherapy. Median time to progression (TTP) is 6.7 months (95% CI: 3.7–13.5). Thirteen out of 15 pts. are still alive. Conclusions: Combination of radiotherapy and Gemcitabin/Oxaliplatin in pts with LA pancreaticobiliairy cancer is feasible and well-tolerated. The long TTP underlines the potential activity of this regimen. As no DLT has been reached, we will use a dose of 60 mg/m2 Ox for further evaluation. [Table: see text]

scholarly journals Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Junko Umeda ◽  
Takao Itoi ◽  
Atsushi Sofuni ◽  
Fumihide Itokawa ◽  
Toshio Kurihara ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
P53 Protein ◽  
Screening Tests ◽  
Protein Overexpression ◽  
P53 Gene Mutation ◽  
Igg Antibody ◽  
Tract Cancer ◽  
P53 Antibody

Background. Recent diagnostic imaging tests contribute to improving the diagnosis of pancreatobiliary cancers. However, it is not practical to perform these tests for all patients as screening. Thus, less-invasive and simple screening tests are still required. A method to detect the IgG antibody induced in serum against the p53 protein accumulating due to p53 gene mutation, as a biomarker, was developed around 1990.Method. 35 patients with pancreatic cancer, 12 patients with biliary tract cancer, and 31 patients with benign pancreatobiliary diseases were entered into this study. Measurement of serum anti-p53 antibody was conducted in all patients. In addition, the rate of p53 protein overexpression was examined in those cases that could be examined pathologically.Result. Among all patients in the pancreatic cancer and biliary tract cancer groups, there was no patient with serum anti-p53 antibody positive value that exceeded the standard value. The rate of p53 protein overexpression was 48.0% in the patients with pancreatobiliary cancers and 0% in the benign pancreatobiliary diseases group.Conclusion. Serum anti-p53 antibody measurement does not contribute to the diagnosis of pancreatobiliary cancers. Instead, traditional p53 immunostaining still appears to be valuable in combination with standard procedures.

scholarly journals PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 558 ◽  
Author(s):  
Alessandro Rizzo ◽  
Angela Dalia Ricci ◽  
Giovanni Brandi
Keyword(s):  
Biliary Tract ◽  
Anticancer Agents ◽  
Biliary Tract Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Primary Liver Cancer ◽  
Tract Cancer ◽  
Predictors Of Response ◽  
Tumor Mutational Burden

Biliary tract cancer (BTC) represents the second most frequently diagnosed primary liver cancer worldwide following hepatocellular carcinoma, and the overall survival of patients with unresectable disease remains poor. In recent years, the advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic landscape of several malignancies with these agents, which have also been explored in advanced BTC, as monotherapy or in combination with other anticancer agents. However, clinical trials evaluating ICIs in BTC have shown conflicting results, and the clinical benefit provided by immunotherapy seems limited to a small subgroup of BTC patients. Thus, the identification of reliable predictors of the response to immunotherapy represents a significant challenge in this setting. This review provides an overview of the available evidence on the biomarkers predictive of the response to ICIs in patients with advanced BTC, especially focusing on programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), microsatellite instability (MSI), and other emerging biomarkers.

scholarly journals Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer

2019 ◽  
Vol 35 (1) ◽  
pp. 28-37 ◽  
Author(s):  
Lukas Perkhofer ◽  
Alica K. Beutel ◽  
Thomas J. Ettrich
Keyword(s):  
Pancreatic Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Tract Cancer

scholarly journals Time-resolved Immunofluorometric Assay of Trypsin-1 Complexed with α1-Antitrypsin in Serum: Increased Immunoreactivity in Patients with Biliary Tract Cancer

1999 ◽  
Vol 45 (10) ◽  
pp. 1768-1773 ◽  
Author(s):  
Johan Hedström ◽  
Caj Haglund ◽  
Esko Kemppainen ◽  
Maarit Leinimaa ◽  
Jari Leinonen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Biliary Tract Disease ◽  
Hepatocellular Cancer ◽  
Receiver Operating Curve ◽  
Biliary Disease ◽  
Time Resolved ◽  
Tract Cancer ◽  
Tract Disease

Abstract Background: Increased serum concentrations of trypsin immunoreactivity occur in patients with biliary tract cancer. To characterize this trypsin, we developed a sensitive time-resolved immunofluorometric assay for trypsin-1 complexed with α1-antitrypsin (AAT) and studied the concentrations of this complex in sera from healthy individuals (n = 130) and patients with benign biliary disease (n = 32), biliary tract cancer (n = 17), pancreatic cancer (n = 27), and hepatocellular cancer (n = 12). Methods: We used a trypsin-1-specific monoclonal antibody on the solid phase and a europium-labeled polyclonal antibody to AAT as tracer. The detection limit was 0.42 μg/L. The validity of the trypsin-1-AAT test for detection of biliary tract cancer was compared with trypsin-2-AAT and CA19-9. Results: Increased concentrations of trypsin-1-AAT (>33 μg/L) were found in 76% of patients with biliary tract cancer, and the concentrations were significantly higher than in those with benign biliary disease (P <0.0001). The median concentration of trypsin-1-AAT in serum from patients with biliary tract cancer was 3.7-fold higher than in healthy controls, 2.6-fold higher than in patients with benign biliary tract disease, 1.7-fold higher than in patients with pancreatic cancer, and 2.0-fold higher than in patients with hepatocellular cancer. Conclusions: Of the markers studied, trypsin-1-AAT had the largest area (0.83) under the receiver operating curve in differentiating biliary tract cancer from benign biliary tract disease. Our results suggest that trypsin-1-AAT is a new potential marker for biliary tract cancer.

Sign in / Sign up

Export Citation Format

Share Document